Test Directory - Understand Your Tests.

K076-IgE Isocyanate MDI

Expected Turnaround Time 3 - 4 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Specimen Requirements Specimen Serum Volume 0.2 mL Minimum Volume 0.1 mL Container Red-top tube or gel-barrier tube Storage Instructions Room temperature Test Details Use Detect possible allergic responses to various substances in the environment such as animals, antibiotics, foods, grasses, house dust, mites, insects, insulin, molds, smuts, trees, and weeds; evaluate hay fever, asthma, atopic eczema, and respiratory allergy. Quantitative allergen-specific IgE test is indicated: • To determine if a patient has elevated allergen-specific IgE antibodies; • If specific allergic sensitivity is needed to allow immunotherapy to be initiated; • When testing patients for agents that may potentially cause anaphylaxis; • When evaluating patients who are taking medications (eg, long-acting antihistamines), which interfere with other testing modalities (eg, skin testing); • If immunotherapy or other therapeutic measures based on skin testing results have not led to a satisfactory remission of symptoms; • When patient is unresponsive to medical management where identification of offending allergens may be beneficial. Methodology Thermo Fisher ImmunoCAP®

K077-IgE Isocyanate HDI

Expected Turnaround Time 3 - 4 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Specimen Requirements Specimen Serum Volume 0.2 mL Minimum Volume 0.1 mL Container Red-top tube or gel-barrier tube Storage Instructions Room temperature Test Details Use Detect possible allergic responses to various substances in the environment such as animals, antibiotics, foods, grasses, house dust, mites, insects, insulin, molds, smuts, trees, and weeds; evaluate hay fever, asthma, atopic eczema, and respiratory allergy. Quantitative allergen-specific IgE test is indicated: • To determine if a patient has elevated allergen-specific IgE antibodies; • If specific allergic sensitivity is needed to allow immunotherapy to be initiated; • When testing patients for agents that may potentially cause anaphylaxis; • When evaluating patients who are taking medications (eg, long-acting antihistamines), which interfere with other testing modalities (eg, skin testing); • If immunotherapy or other therapeutic measures based on skin testing results have not led to a satisfactory remission of symptoms; • When patient is unresponsive to medical management where identification of offending allergens may be beneficial. Methodology Thermo Fisher ImmunoCAP®

K078-IgE Ethylene Oxide

Expected Turnaround Time 3 - 4 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Specimen Requirements Specimen Serum Volume 0.2 mL Minimum Volume 0.1 mL Container Red-top tube or gel-barrier tube Storage Instructions Room temperature Test Details Use Detect possible allergic responses to various substances in the environment such as animals, antibiotics, foods, grasses, house dust, mites, insects, insulin, molds, smuts, trees, and weeds; evaluate hay fever, asthma, atopic eczema, and respiratory allergy. Quantitative allergen-specific IgE test is indicated: • To determine if a patient has elevated allergen-specific IgE antibodies; • If specific allergic sensitivity is needed to allow immunotherapy to be initiated; • When testing patients for agents that may potentially cause anaphylaxis; • When evaluating patients who are taking medications (eg, long-acting antihistamines) that interfere with other testing modalities (eg, skin testing); • If immunotherapy or other therapeutic measures based on skin testing results have not led to a satisfactory remission of symptoms; • When patient is unresponsive to medical management where identification of offending allergens may be beneficial. Methodology Thermo Fisher ImmunoCAP®

K079-IgE Phthalic Anhydride

Expected Turnaround Time 3 - 4 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Specimen Requirements Specimen Serum Volume 0.2 mL Minimum Volume 0.1 mL Container Red-top tube or gel-barrier tube Storage Instructions Room temperature Test Details Use Detect possible allergic responses to various substances in the environment such as animals, antibiotics, foods, grasses, house dust, mites, insects, insulin, molds, smuts, trees, and weeds; evaluate hay fever, asthma, atopic eczema, and respiratory allergy. Quantitative allergen-specific IgE test is indicated: • To determine if a patient has elevated allergen-specific IgE antibodies; • If specific allergic sensitivity is needed to allow immunotherapy to be initiated; • When testing patients for agents that may potentially cause anaphylaxis; • When evaluating patients who are taking medications (eg, long-acting antihistamines), which interfere with other testing modalities (eg, skin testing); • If immunotherapy or other therapeutic measures based on skin testing results have not led to a satisfactory remission of symptoms; • When patient is unresponsive to medical management where identification of offending allergens may be beneficial. Methodology Thermo Fisher ImmunoCAP®

K080-IgE Formaldehyde

Expected Turnaround Time 3 - 4 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Specimen Requirements Specimen Serum Volume 0.2 mL Minimum Volume 0.1 mL Container Red-top tube or gel-barrier tube Storage Instructions Room temperature Test Details Use Detect possible allergic responses to various substances in the environment such as animals, antibiotics, foods, grasses, house dust, mites, insects, insulin, molds, smuts, trees, and weeds; evaluate hay fever, asthma, atopic eczema, and respiratory allergy. Quantitative allergen-specific IgE test is indicated: • To determine if a patient has elevated allergen-specific IgE antibodies; • If specific allergic sensitivity is needed to allow immunotherapy to be initiated; • When testing patients for agents that may potentially cause anaphylaxis; • When evaluating patients who are taking medications (eg, long-acting antihistamines), which interfere with other testing modalities (eg, skin testing); • If immunotherapy or other therapeutic measures based on skin testing results have not led to a satisfactory remission of symptoms; • When patient is unresponsive to medical management where identification of offending allergens may be beneficial. Methodology Thermo Fisher ImmunoCAP®

K086-IgE Trimellitic Anhydrid

Expected Turnaround Time 3 - 4 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Specimen Requirements Specimen Serum Volume 0.2 mL Minimum Volume 0.1 mL Container Red-top tube or gel-barrier tube Storage Instructions Room temperature Test Details Use Detect possible allergic responses to various substances in the environment such as animals, antibiotics, foods, grasses, house dust, mites, insects, insulin, molds, smuts, trees, and weeds; evaluate hay fever, asthma, atopic eczema, and respiratory allergy. Quantitative allergen-specific IgE test is indicated: • To determine if a patient has elevated allergen-specific IgE antibodies; • If specific allergic sensitivity is needed to allow immunotherapy to be initiated; • When testing patients for agents that may potentially cause anaphylaxis; • When evaluating patients who are taking medications (eg, long-acting antihistamines), which interfere with other testing modalities (eg, skin testing); • If immunotherapy or other therapeutic measures based on skin testing results have not led to a satisfactory remission of symptoms; • When patient is unresponsive to medical management where identification of offending allergens may be beneficial. Methodology Thermo Fisher ImmunoCAP®

Kaolin Clotting Time (KCT)

Expected Turnaround Time 3 - 5 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Related Information Lupus Anticoagulant Comprehensive Lupus Anticoagulant With Reflex Partial Thromboplastin Time (PTT), Activated Related Documents For more information, please view the literature below. Procedures for Hemostasis and Thrombosis: A Clinical Test Compendium Sample Report Specimen Requirements Specimen Plasma (platelet poor), frozen Volume 2 mL Minimum Volume 1 mL Container Blue-top (sodium citrate) tube Collection Citrated plasma samples should be collected by double centrifugation. Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate.1 Evacuated collection tubes must be filled to completion to ensure a proper blood-to-anticoagulant ratio.2,3 The sample should be mixed immediately by gentle inversion at least six times to ensure adequate mixing of the anticoagulant with the blood. A discard tube is not required prior to collection of coagulation samples except when using a winged blood collection device (ie, "butterfly"), in which case a discard tube should be used.4,5 When noncitrate tubes are collected for other tests, collect sterile and nonadditive (red-top) tubes prior to citrate (blue-top) tubes. Any tube containing an alternate anticoagulant should be collected after the blue-top tube. Gel-barrier tubes and serum tubes with clot initiators should also be collected after the citrate tubes. Centrifuge and carefully remove the plasma using a plastic transfer pipette, being careful not to disturb the cells. Transfer the plasma into a LabCorp PP transpak frozen purple tube with screw cap (LabCorp N° 49482). Freeze immediately and maintain frozen until tested. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested. Please print and use the Volume Guide for Coagulation Testing to ensure proper draw volume. Storage Instructions Freeze. Stable at room temperature for four hours. Patient Preparation Do not draw from an arm with a heparin lock or heparinized catheter. Test Details Use The KCT is a sensitive screening test of lupus anticoagulants (LA) in patients with a history of thrombosis.6-10 Limitations This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). Methodology In the kaolin clotting time (KCT) test, kaolin, a negatively-charged particulate activator, is incubated with test plasma to activate the contact factors and the intrinsic system.11 Calcium chloride is added and the mixture is timed until a clot forms. Additional Information The intrinsic mechanism requires the presence of all coagulation factors except factor VII and XIII. In the KCT, unlike TTIT, dRVVT, and aPTT, no reagent phospholipid is added, so plasma phospholipids are required for the reaction to proceed. For this reason, the KCT is sensitive to the presence of lupus anticoagulants, when if present, will generally prolong the KCT. All clot-based tests are potentially affected by factor deficiencies. The KCT is prolonged in any except factor VII or XIII deficiency. Lupus anticoagulants are nonspecific antibodies that extend the clotting time of phospholipid-dependent clotting assays such as the KCT.7,10 Unlike specific factor antibodies, LA are usually associated with venous thrombosis, pulmonary embolism, arterial thrombosis, and recurrent fetal loss.12 LA do not specifically inhibit coagulation factors; rather they neutralize anionic phospholipid-protein complexes that are involved in the coagulation process. Prolongation of clot-based assays is highly dependent on the sensitivity of the reagent employed. Reagents with reduced amounts of phospholipid, such as KCT, aPTT-LA, and dilute Russell viper venom (dRVVT), have enhanced sensitivity for LA.7 Testing for lupus anticoagulant (LA) and the antiphospholipid syndrome that is associated with these antibodies is described in more detail in the APS section. The KCT is sensitive to deficiency or inhibition of factors in the intrinsic pathway. These include the contact factors; high molecular weight kininogen (HMWK); prekallikrein; and factor XII along with procoagulant factors XI, IX, VIII, X, V, prothrombin, and fibrinogen.10,12-14 An extended KCT can be seen in acquired deficiencies of intrinsic factors II, IX, and X that result from vitamin K deficiency or the use of oral anticoagulants that block vitamin K-dependent production of procoagulant factors. These conditions also affect the level of factor VII, an extrinsic pathway factor. Since factor VII has a short half-life relative to the vitamin K-dependent factors of the intrinsic pathway, vitamin K-dependent factor deficiency can often result in an extended PT with a normal aPTT and KCT. Consumption coagulopathy, such as disseminated intravascular coagulation (DIC), can produce an extended KCT due to depletion of intrinsic factors. The KCT can also be extended in conditions that reduce the production of procoagulant factors (eg, severe liver disease or malnutrition). Inhibitors, both factor specific and nonspecific, can also prolong the KCT.

Kentucky Bluegrass

Expected Turnaround Time 2 - 4 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Related Information Individual Allergens Related Documents Sample Report Specimen Requirements Specimen Serum Volume 1 mL Container One 8.5 mL red-top tube or one 8.5 mL gel-barrier tube Storage Instructions Room temperature Stability Requirements Temperature Period Room temperature 14 days Refrigerated 14 days Frozen 3 months Freeze/thaw cycles Stable x3 Test Details Methodology Thermo Fisher ImmunoCAP®

Ketamine and Metabolite, Quantitative, Serum or Plasma

Synonyms Ketalar® Test Includes Ketamine; norketamine Expected Turnaround Time 7 - 14 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Specimen Requirements Specimen Serum or plasma Volume 2 mL Container Red-top tube or gray-top (sodium fluoride) tube. Gel-barrier tubes are not recommended. Collection Serum or plasma should be separated from cells within two hours of venipuncture. Submit serum or plasma in a plastic transport tube. Storage Instructions Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen. Patient Preparation Trough levels are most reproducible. Causes for Rejection Gel-barrier tubes Test Details Use Therapeutic drug management; detect presence of ketamine Methodology Liquid chromatography/tandem mass spectrometry (LC/MS-MS)

Ketoconazole, Serum or Plasma

Synonyms Nizoral® Expected Turnaround Time 3 - 7 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Specimen Requirements Specimen Serum (preferred) or plasma Volume 1 mL Minimum Volume 0.5 mL Container Red-top tube or lavender-top (EDTA) tube Collection Transfer separated serum or plasma to a plastic transport tube. Do not use a gel barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage times, the decrease in drug level due to absorption may be clinically significant. Storage Instructions Refrigerate. Stable for 14 days at room temperature, refrigerated, or frozen. Causes for Rejection Gel-barrier tube Test Details Use Treatment of susceptible fungal infections, including candidiasis, oral thrush, blastomycosis, histoplasmosis, paracoccidiodomycosis, coccidioidomycosis, chromomycosis, chronic muccotaneous candidiasis, as well as recalcitrant cutaneous dematophytoses. Limitations This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. Methodology Liquid chromatography/tandem mass spectrometry (LC/MS-MS)

Kidney Bean

Kidney Bean

Kidney Profile

Test Includes Creatinine, serum; eGFR calculation; albumin, random urine; creatinine, urine; albumin:creatinine ratio, urine Expected Turnaround Time Within 1 day Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Related Documents Sample Report Specimen Requirements Specimen Serum (preferred) or plasma and urine (random) Volume 1 mL serum or plasma and 10 mL urine Minimum Volume 0.5 mL serum or plasma and 2 mL urine Container Red-top tube, gel-barrier tube, green-top (heparin) tube, or lavender-top (EDTA) tube and plastic urine container Collection Separate serum or plasma from cells within 45 minutes of collection. Storage Instructions Maintain specimens at room temperature. Stability Requirements Temperature Period Room temperature 7 days Refrigerated 14 days Frozen 14 days Freeze/thaw cycles Stable x3 Causes for Rejection Hemolysis; improper labeling Test Details Use This panel is useful in the identification of patients with early Chronic Kidney Disease and management of patients with relatively early diabetes mellitus to assist in avoiding or delaying the onset of diabetic renal disease. See the individual tests as listed in the Directory of Service for detailed information. Methodology Creatinine: kinetic jaffe; Albumin: immunoturbidimetric

Kidney Stone Urine Test Combination With Saturation Calculations

Test Includes Ammonia; calcium; chloride; citrate; creatinine; cystine; magnesium; osmolality; oxalate; pH; phosphorus; potassium; sodium; sulfate; total volume; uric acid; saturation ratios: brushite, calcium oxalate, monosodium urate, struvite; graph review Expected Turnaround Time 6 - 8 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Related Documents Sample Report Specimen Requirements Specimen Urine (24-hour) Volume Two 100 mL urine aliquots, frozen Container Urine container Collection Collect a single 24-hour urine collection without preservative. Take two 100 mL aliquots of this urine and freeze. Write total volume on aliquot with other clinical information. Also, write total volume on the requisition. Graphic analysis of results is mailed to client. Storage Instructions Freeze. Test Details Use Evaluate stone comp

Killer Immunoglobulin-like Receptors (KIR)

Synonyms Genotyping KIR KIR Typing Transplant Expected Turnaround Time 3 - 9 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Related Documents Sample Report Specimen Requirements Specimen Whole blood Volume 7 mL Minimum Volume 3 mL Container Lavender-top (EDTA) tube Storage Instructions Maintain specimen at room temperature. Causes for Rejection Highly lipemic or hemolyzed specimen Test Details Use The function of natural killer cells in the immune response is regulated by killer immunoglobulin-like receptors (KIR). These receptors interact with class I HLA antigens on the cell surface to prevent or activate killing of the target cell. KIR genotyping may be useful in some stem cell transplants because KIR matching or mismatching can mediate a graft-versus-leukemia effect when the cancer cells are underexpressing HLA class I antigens. Limitations Results for this test are for research purposes only by the assay's manufacturer. The performance characteristics of this product have not been established. Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.

Kiwi Fruit

Expected Turnaround Time 2 - 4 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Related Information Individual Allergens Related Documents Sample Report Specimen Requirements Specimen Serum Volume 0.2 mL Container Red-top tube or gel-barrier tube Storage Instructions Room temperature Stability Requirements Temperature Period Room temperature 14 days Refrigerated 14 days Frozen 3 months Freeze/thaw cycles Stable x3 Test Details Methodology Thermo Fisher ImmunoCA

Known Familial Mutation Sequencing Analysis (Endocrine Sciences)

Synonyms Known mutation Special Instructions Client must contact the laboratory before ordering. Documentation of known familial mutation is required. DNA sample from index patient as a positive control is recommended. Expected Turnaround Time 21 - 28 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Related Documents For more information, please view the literature below. Clinical Questionnaire for Known Familial Mutation, Endo Sample Report Specimen Requirements Specimen Whole blood or extracted DNA Volume 3 mL Minimum Volume 1 mL (Note: This volume does not allow for repeat testing) Container Lavender-top (EDTA) tube or yellow-top (ACD) tube Storage Instructions Maintain specimen at room temperature. Stability: Room temperature up to 28 days; refrigerated up to 28 days Causes for Rejection Hemolysis; frozen specimen Test Details Use Single exon sequence is performed to help clarify the genetic status of appropriate, at-risk members of a family where a gene mutation has previously been identified. Limitations Polymorphisms or some sequence variants that affect PCR efficiency, incorrect familial relationship or mutation information provided by the client; only the exon containing the mutation in question is being tested. Methodology Polymerase Chain Reaction (PCR) of a single targeted gene exone, followed by bidirectional Sanger sequencing of a single PCR product

Kochia

Expected Turnaround Time 3 - 4 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Related Information Individual Allergens Related Documents Sample Report Specimen Requirements Specimen Serum Volume 0.2 mL Container Red-top tube or gel-barrier tube Storage Instructions Room temperature Stability Requirements Temperature Period Room temperature 14 days Refrigerated 14 days Frozen 3 months Freeze/thaw cycles Stable x3 Test Details Methodology Thermo Fisher ImmunoCAP®

KRAS Gene Mutation Analysis, Colorectal Cancer (CRC)

Special Instructions Please provide a copy of the pathology report. Direct any questions regarding this test to customer service at 800-345-4363. Expected Turnaround Time 5 - 7 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Related Documents For more information, please view the literature below. K-ras Mutation Analysis Specimen Requirements Specimen Formalin-fixed, paraffin-embedded (FFPE) tissue block or slides from colorectal cancer Volume Four unstained slides and one matching H&E-stained slide at 5 μM or formalin-fixed, paraffin-embedded tissue block Minimum Volume Two unstained slides and one matching H&E-stained slide at 5 μM. Samples with >4 mm² and ≥20% tumor content are preferred. Container Slides, blocks Storage Instructions Maintain specimen at room temperature up to 4 weeks at 15-30°C. Causes for Rejection Tumor block containing no tumor tissue; tumor fixed in a heavy metal fixative; broken or stained slides Test Details Use This KRAS assay is a real-time qualitative PCR test performed on the Rotor-Gene Q MDx instrument for the detection of the seven most common somatic mutations in the human KRAS oncogene, using DNA extracted from formalin-fixed paraffin-embedded (FFPE), colorectal cancer (CRC) tissue. This assay is intended to aid in the identification of CRC patients for treatment with cetuximab (Erbitux®), based on a KRAS "no mutation detected" test result. The presence of these mutations correlates with a lack of response for certain EGFR inhibitor cancer therapies in patients with metastatic colorectal cancer. Limitations The KRAS test is designed to detect seven mutations in codons 12 and 13 of the KRAS gene. These seven mutations account for >97% of all reported KRAS mutations in CRC patients. Samples with results reported as "no mutation detected" may harbor KRAS mutations that are not detected by the assay. Detection of mutation is dependent on sample integrity and the amount of amplifiable DNA present in the specimen. The methods used in this assay are highly selective and, depending on the total amount of DNA present, can detect approximately 1% to 5% of mutant DNA in a background of wild-type genomic DNA. Methodology Amplification refractory mutation system (ARMS) and real-time polymerase chain reaction (PCR) using Scorpions™ technology

KRAS Gene Mutation Analysis, Extended

Special Instructions Provide a copy of the pathology report; the KRAS test will be delayed if the pathology report is not received. Direct any questions regarding this test to customer service at 800-345-4363. Expected Turnaround Time 5 - 7 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Related Information BRAF Gene Mutation Analysis KRAS Gene Mutation Analysis, Extended NRAS Gene Mutation Analysis, Extended Specimen Requirements Specimen Formalin-fixed, paraffin-embedded (FFPE) tissue block or slides. Volume Formalin-fixed, paraffin-embedded tissue block or four unstained slides and one matching H&E-stained slide at 5 µM. Minimum Volume Two unstained slides and one matching H&E-stained slide at 5 μM. Samples with >4 mm² and ≥50% tumor content are preferred. Container FFPE tissue blocks or slides. Storage Instructions Maintain blocks and slides at room temperature. Causes for Rejection Tumor block containing no tumor tissue; broken or stained slides Test Details Use KRAS is a guanosine triphosphate (GTP) binding protein involved in downstream receptor signaling, which is critical for cell proliferation, survival, and differentiation. Mutations in the KRAS oncogene are frequently found in human cancers. They are common in pancreatic, colorectal, lung, gallbladder, bile duct, and thyroid cancer. This assay will detect KRAS mutations in exons 2, 3, and 4, allowing the determination of drug response. Limitations This assay is able to detect 5% mutation in a background of wild-type DNA. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). Methodology SNaPshot Multiplex PCR (primer extension-based method)

Kratom (Mitragynine), Screen and Confirmation, Urine

Test Includes 7-Hydroxymitragynine; mitragynine Expected Turnaround Time 5 - 10 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary. Related Documents Sample Report Specimen Requirements Specimen Urine (random) Volume 10 mL Minimum Volume 1 mL Container Plastic urine container without preservative Storage Instructions Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen. Causes for Rejection Urine from preservative tube Test Details Use Detect presence of the kratom alkaloid mitragynine, which has both stimulant and opioid effects Methodology Initial presumptive testing by liquid chromatography/tandem mass spectrometry (LC/MS-MS) at a testing threshold of 1.0 ng/mL; presumptive positives confirmed by definitive liquid chromatography/tandem mass spectrometry (LC/MS-MS) at a testing threshold of 1.0 ng/mL